[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360030-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360030-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","impact-of-egfr-mutations-on-survival-and-clinical-response-in-non-small-cell-lung-cancer-in-a-tertiary-care-hospital","Impact of EGFR Mutations on Survival and Clinical Response in Non-Small Cell Lung Cancer in a Tertiary Care Hospital","","Lung cancer remains a major cause of cancer morbidity and mortality, making reliable prognostic factors essential to improve outcomes. This prospective cohort study analyzed 70 non-small cell lung cancer (NSCLC) patients to evaluate how clinical, demographic, and EGFR genetic factors relate to overall survival (OS) and progression-free survival (PFS). Survival was estimated using Kaplan–Meier analysis with log-rank testing and RECIST 1.1 clinical response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-egfr-mutations-on-survival-and-clinical-response-in-non-small-cell-lung-cancer-in-a-tertiary-care-hospital/360030/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-egfr-mutations-on-survival-and-clinical-response-in-non-small-cell-lung-cancer-in-a-tertiary-care-hospital/360030.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective in NSCLC patients?","Question",{"text":63,"@type":64},"To assess how clinical, demographic, and genetic factors—especially EGFR mutation status—impact overall survival (OS) and progression-free survival (PFS) in NSCLC patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were RECIST 1.1 clinical responses and survival outcomes evaluated?",{"text":68,"@type":64},"Clinical response was assessed using RECIST 1.1 criteria, and OS/PFS outcomes were estimated with Kaplan–Meier methods and compared using the log-rank test.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were identified as key predictors of survival?",{"text":72,"@type":64},"EGFR mutation status, brain metastases, and clinical response were reported as key predictors of survival in NSCLC patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360030,1790193907,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Clinical and Translational Science  \nImpact of EGFR Mutations on Survival and Clinical Response in Non-Small Cell Lung Cancer in a Tertiary Care Hospital  \nGayathri Baburaj1,2  | Ananth Pai3  | Varun Kumar Sudha Gururaj4  | Satyanarayana Poojari4  | Mahadev Rao2  | Karthik S. Udupa3   \n1Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India | 2Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal,  \nKarnataka, India | 3Department of Medical Oncology, Kasturba Medical College & Hospital, Manipal Academy of Higher Education, Manipal, Karnataka,  \nIndia | 4Department of Data Science, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India Correspondence: Mahadev Rao ([mahadev.rao@manipal.edu](mahadev.rao@manipal.edu)) | Karthik S. Udupa ([udupa.karthik@manipal.edu](udupa.karthik@manipal.edu))  \nReceived: 18 November 2025 | Revised: 19 March 2026 | Accepted: 20 April 2026  \nKeywords: lung cancer | overall survival | progression-free survival | treatment response  \nABSTRACT  \nLung cancer continues to be the leading cause of morbidity and mortality associated with malignancies. Identifying prognostic factors is vital for improving survival outcomes. This study assessed the impact of clinical, demographic, and genetic factors on overall survival (OS) and progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) . A prospective cohort of 70 NSCLC patients was analyzed. Demographic and clinical data, including epidermal growth factor receptor (EGFR) mutation status and clinical response by RECIST 1.1 criteria, were assessed. Survival outcomes were estimated using the Kaplan–Meier method with log-rank test. The median PFS and OS were 15 and 24 months, respectively. EGFR-positive patients showed significantly longer survival than EGFR-negative patients (PFS: 17 vs. 11 months, OS: not reached [NA] vs. 24 months) . Brain metastases indicated poor OS (OS: 15 months vs. NA) but did not affect PFS. Patients with a partial response after one year exhibited improved overall survival (24-month OS probability of 77.8%) . EGFR mutation status, brain metastases, and clinical response are key predictors of survival in NSCLC patients. Integrating genetic screening, timely management of brain metastases, and early assessment may enhance personalized treatment and improve prognosis.  \n1 | Introduction  \nLung cancer continues to be the most commonly diagnosed cancer worldwide, constituting one in eight (12.4%) of total cases and one in five (18.7%) of total deaths, as reported by GLOBOCAN 2022 [1] . With 2.5 million new cases and over 1.8 million deaths, it is the leading cause of cancer morbidity and mortality [1] . According to the National Cancer Registry Programme (NCRP)  \nreport, the number of cases in India is anticipated to increase significantly in 2025, with 81,219 cases for males and 30,109 cases for females [2] .  \nNon-small cell lung cancer (NSCLC), the most prevalent subtype, accounts for approximately 85% of all lung cancer cases [3] . Several therapies are available for NSCLC, including surgical intervention, chemotherapy, radiation, targeted therapy, and  \n\n| Gayathri Baburaj and Ananth Pai contributed equally to this work.\u003Cbr>Mahadev Rao and Karthik S. Udupa are co-corresponding authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |\n\nClinical and Translational Science, 2026; 19:e70579 1 of 10  \n[https://doi.org/10.1111","cbCaia1gDxfmI3hW","https://ap.wps.com/l/cbCaia1gDxfmI3hW","pdf",1028914,"English","# Introduction\n## Study Highlights","[{\"question\":\"What was the study’s main objective in NSCLC patients?\",\"answer\":\"To assess how clinical, demographic, and genetic factors—especially EGFR mutation status—impact overall survival (OS) and progression-free survival (PFS) in NSCLC patients.\"},{\"question\":\"How were RECIST 1.1 clinical responses and survival outcomes evaluated?\",\"answer\":\"Clinical response was assessed using RECIST 1.1 criteria, and OS/PFS outcomes were estimated with Kaplan–Meier methods and compared using the log-rank test.\"},{\"question\":\"Which factors were identified as key predictors of survival?\",\"answer\":\"EGFR mutation status, brain metastases, and clinical response were reported as key predictors of survival in NSCLC patients.\"}]","Impact of EGFR Mutations on Survival and Clinical Response in Non-Small Cell Lung Cancer in a Tertiary Care Hospital | PDF",1790138542,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7eabb7e1cde44cbf3235a2a9d45ece87.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed1b612675ec6d15ee3ca3fdd6b5d41e.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b3394747db386377d42fc4abf74aeb0.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c453045aecbf6f1eca5079565b01230f.webp",980,1287]